Changyou Zhou

发表

Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors.

Michael E. Lassman, Shirly Pinto, M. Garcia-Calvo, 2011, Bioorganic & medicinal chemistry letters.

Design and syntheses of melanocortin subtype-4 receptor agonists: evolution of the pyridazinone archetype.

F. Ujjainwalla, L. V. D. van der Ploeg, C. Rosenblum, 2003, Bioorganic & medicinal chemistry letters.

Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice

Yun-ping Zhou, J. Berger, N. Thornberry, 2008, Diabetes.

Discovery of novel dihydrobenzofuran cyclopropane carboxylic acid based calcium sensing receptor antagonists for the treatment of osteoporosis.

D. Zaller, H. Wilkinson, P. Meinke, 2016, Bioorganic & Medicinal Chemistry Letters.

Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists.

Yun-ping Zhou, J. Berger, N. Thornberry, 2010, Bioorganic & medicinal chemistry letters.

3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.

A. Howard, Carina P. Tan, G. Eiermann, 2011, Bioorganic & medicinal chemistry letters.

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Zhiwei Wang, X. Liu, Xiaomin Song, 2019, Journal of medicinal chemistry.

Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity.

Kenny K. Wong, Shirly Pinto, R. S. Roy, 2010, Journal of medicinal chemistry.

Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.

M. Struthers, M. Maccoss, J. Demartino, 2009, Bioorganic & medicinal chemistry letters.

Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.

M. Maccoss, W. Hanlon, G. Butora, 2006, Bioorganic & medicinal chemistry letters.

Discovery of 3-piperidinyl-1-cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists.

M. Maccoss, G. Butora, W. Parsons, 2007, Journal of medicinal chemistry.

α-Aminothiazole-γ-aminobutanoic amides as potent, small molecule CCR2 receptor antagonists

M. Maccoss, W. Parsons, Changyou Zhou, 2007 .

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

J. Ji, Xiaoxiao Hu, S. Cheung, 2015, Molecular Cancer Therapeutics.

Abstract 1651: BGB-290, a novel PARP inhibitor with unique brain penetration ability, demonstrated strong synergism with temozolomide in subcutaneous and intracranial xenograft models

B. Jiang, Zhe Shi, L. Luo, 2015 .

Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma

G. Prendergast, D. Munn, J. Raizer, 2020, Clinical Cancer Research.

Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor

X. Liu, Xiaomin Song, Zhirong Shen, 2020, Neoplasia.

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.

Zhiwei Wang, X. Liu, L. Luo, 2020, Journal of medicinal chemistry.

Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases.

Yuehua Wu, X. Liu, Shuaishuai Chen, 2023, Journal of medicinal chemistry.

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

N. Rosen, Paul D. Smith, Xiaoxiao Hu, 2020, Molecular oncology.

Abstract 1653: BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models

B. Jiang, Zhe Shi, Jun Zhao, 2015 .

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.

Zhiwei Wang, X. Liu, L. Luo, 2020, Journal of medicinal chemistry.